Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 7/20 | 0.35 |
| ▸ | BRAF | P15056 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13114873 | 0.91 | ADRA2A (0.39) | BRD4MAP2K1MAP2K2BRAFKIT | |
| SCHEMBL1343822 | 0.85 | BRD4 (0.44) | IDO1BRD4MAP2K1MAP2K2BRAF | |
| SCHEMBL1343469 | 0.85 | MAP2K1 (0.41) | IDO1BRD4MAP2K1MAP2K2BRAF | |
| SCHEMBL1343602 | 0.84 | IDO1 (0.40) | IDO1MAP2K1MAP2K2CHEK1MAPK10 | |
| SCHEMBL16774785 | 0.84 | BRD4 (0.37) | BRD4BRAFKIT | |
| SCHEMBL1343152 | 0.82 | MAP2K1 (0.39) | IDO1BRD4MAP2K1MAP2K2BRAF | |
| SCHEMBL1343442 | 0.81 | MAP2K1 (0.46) | IDO1MAP2K1MAP2K2BRAFCHEK1 | |
| SCHEMBL16803288 | 0.81 | MAP2K1 (0.42) | IDO1MAP2K1MAP2K2CHEK1MAPK10 | |
| SCHEMBL15129697 | 0.79 | IDO1 (0.37) | IDO1MAP2K1MAP2K2BRAFCHEK1 | |
| SCHEMBL1343588 | 0.79 | MAP2K1 (0.39) | BRD4MAP2K1MAP2K2BRAFAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2175885-B1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES INC (US) | 2016-10-12 | — | — | EP | disclosed |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2016-09-22 | — | — | US | disclosed |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | US | disclosed |
| US-9095581-B2 | Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof | ARDEA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| EP-2121620-B1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES INC (US) | 2015-06-17 | — | — | EP | disclosed |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. | 2012-05-31 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063049-B2 | Inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331334-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. | 2010-12-30 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| US-7820664-B2 | Inhibitors of MEK | BAYER SCHERING PHARMA AG (DE) | 2010-10-26 | — | — | US | disclosed |
| EP-2121620-A1 | INHIBITORS OF MEK | Ardea Biosciences, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009018238-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | ARDEA BIOSCIENCES, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | ARDEA BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008089459-A1 | INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255133-A1 | N-(2-aylamino)aryl sulfonamides such as N-(7-(4-bromo-2-fluorophenylamino)imidazo[1,2-b]pyridazin-6-yl)-1-(2-hydroxyethyl)cyclopropane-1-sulfonamide; mitogen-activated ERK activating kinase (MEK) inhibitors; antiproliferative, anticarcinogenic, and antiinflammatory agents | MAPK8, MAP3K8, MAP3K2 | IDO1 653/4885BRD4 269/4885MAP2K1 51/4885 |
| US-20120136030-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | IDO1 2340/4885BRD4 1043/4885MAP2K1 71/4885 |
| US-20100331334-A1 | INHIBITORS OF MEK | NRAS, BRAF, KSR2 | IDO1 1390/4885BRD4 479/4885MAP2K1 54/4885 |
| US-20160271122-A1 | COMBINATIONS OF MEK INHIBITORS AND RAF KINASE INHIBITORS AND USES THEREOF | BRAF, RAF1, NRAS | IDO1 2340/4885BRD4 1043/4885MAP2K1 71/4885 |
| US-20150267258-A1 | BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS | NRAS, KRAS, TP53 | IDO1 3860/4885BRD4 809/4885MAP2K1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.